Want FREE Templates on Organization, Change, & Culture? Download our FREE compilation of 50+ slides. This is an exclusive promotion being run on LinkedIn.

Market Overview: Breast Cancer   29-page PDF document
$299.00

Market Overview: Breast Cancer (29-page PDF document) Preview Image Market Overview: Breast Cancer (29-page PDF document) Preview Image Market Overview: Breast Cancer (29-page PDF document) Preview Image Market Overview: Breast Cancer (29-page PDF document) Preview Image Market Overview: Breast Cancer (29-page PDF document) Preview Image Market Overview: Breast Cancer (29-page PDF document) Preview Image Market Overview: Breast Cancer (29-page PDF document) Preview Image Market Overview: Breast Cancer (29-page PDF document) Preview Image Market Overview: Breast Cancer (29-page PDF document) Preview Image Log in to unlock full preview.
Arrow   Unlock all 11 preview images:   Login Register

Market Overview: Breast Cancer (PDF)

File Type: 29-page PDF document

$299.00

Add to Cart
  


BUY WITH CONFIDENCE

Immediate digital download upon purchase.
Lifetime document updates included with purchase.
Trusted by over 10,000+ organizations.

BENEFITS OF DOCUMENT

  1. The breast cancer therapy market was the largest in oncology across the major markets
  2. Etiology and Pathophysiology
  3. Key Pathways and Drug Targets

DESCRIPTION

This product (Market Overview: Breast Cancer) is a 29-page PDF document, which you can download immediately upon purchase.

The breast cancer therapy market was the largest in oncology across the major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) in 2015 with sales of $13.8 billion. Sales are set to soar throughout our forecast period to $30.5 billion by 2025, driven by uptake of both current and emerging agents in multiple treatment settings. Two drug classes, HER2-targeted agents and CDK4/6 inhibitors, will account for over 60% of sales in this market in 2025.

Currently approved therapies will continue to have a meaningful impact on the breast cancer treatment algorithm and market sales. Pfizer's CDK4/6 inhibitor Ibrance will experience increasing use in the HR-positive, HER2-negative population, fueling this agent's sales to exceed $8.5 billion at its peak. Roche/Genentech/Chugai's HER2-targeted MAb, Perjeta, will continue to gain traction in the market, with its forecast adjuvant approval bolstering sales to exceed $5 billion in 2025.

Introduction
Key Findings
Market Share of Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Healthcare, Cancer PDF: Market Overview: Breast Cancer PDF (PDF) Document, pharmzolgas


$299.00

Add to Cart
  

OVERVIEW

File Type: PDF pdf (PDF)
File Size: 1.7 MB
Number of Pages: 29

ABOUT THE AUTHOR

Author: pharmzolgas
Additional documents from author: 3

Ask the Author a Question

Must be logged in

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.




Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab




Read Customer Testimonials





Customers Also Like These Documents

Related Management Topics


Healthcare Integrated Financial Model Cancer Value Chain Analysis ESG Scheduling

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.